JP3790472B2 - ヘテロ多環式化合物および代謝型グルタミン酸受容体アンタゴニストとしてのその使用 - Google Patents

ヘテロ多環式化合物および代謝型グルタミン酸受容体アンタゴニストとしてのその使用 Download PDF

Info

Publication number
JP3790472B2
JP3790472B2 JP2001517525A JP2001517525A JP3790472B2 JP 3790472 B2 JP3790472 B2 JP 3790472B2 JP 2001517525 A JP2001517525 A JP 2001517525A JP 2001517525 A JP2001517525 A JP 2001517525A JP 3790472 B2 JP3790472 B2 JP 3790472B2
Authority
JP
Japan
Prior art keywords
pyridyl
oxazole
oxadiazole
cyanophenyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001517525A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003507378A5 (enExample
JP2003507378A (ja
Inventor
ワゲネン，ブラッドフォード，シー． ヴァン
ストーマン，トーマス，エム．
モエ，スコット，ティー．
シーハン，スーザン，エム．
マクレオド，ドナルド，エー．
スミス，ダリル，エル．
イザーク，メスヴィン，ベンジャミン
スラッシ，アブデルマリク
Original Assignee
エヌピーエス ファーマシューティカルズ インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22530400&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP3790472(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by エヌピーエス ファーマシューティカルズ インコーポレーテッド filed Critical エヌピーエス ファーマシューティカルズ インコーポレーテッド
Publication of JP2003507378A publication Critical patent/JP2003507378A/ja
Publication of JP2003507378A5 publication Critical patent/JP2003507378A5/ja
Application granted granted Critical
Publication of JP3790472B2 publication Critical patent/JP3790472B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
JP2001517525A 1999-08-19 2000-08-18 ヘテロ多環式化合物および代謝型グルタミン酸受容体アンタゴニストとしてのその使用 Expired - Fee Related JP3790472B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14946499P 1999-08-19 1999-08-19
US60/149,464 1999-08-19
PCT/US2000/022618 WO2001012627A1 (en) 1999-08-19 2000-08-18 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006016914A Division JP2006143746A (ja) 1999-08-19 2006-01-25 ヘテロ多環式化合物および代謝型グルタミン酸受容体アンタゴニストとしてのその使用

Publications (3)

Publication Number Publication Date
JP2003507378A JP2003507378A (ja) 2003-02-25
JP2003507378A5 JP2003507378A5 (enExample) 2005-12-22
JP3790472B2 true JP3790472B2 (ja) 2006-06-28

Family

ID=22530400

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001517525A Expired - Fee Related JP3790472B2 (ja) 1999-08-19 2000-08-18 ヘテロ多環式化合物および代謝型グルタミン酸受容体アンタゴニストとしてのその使用
JP2006016914A Pending JP2006143746A (ja) 1999-08-19 2006-01-25 ヘテロ多環式化合物および代謝型グルタミン酸受容体アンタゴニストとしてのその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006016914A Pending JP2006143746A (ja) 1999-08-19 2006-01-25 ヘテロ多環式化合物および代謝型グルタミン酸受容体アンタゴニストとしてのその使用

Country Status (27)

Country Link
EP (1) EP1210344B1 (enExample)
JP (2) JP3790472B2 (enExample)
KR (1) KR100875222B1 (enExample)
CN (1) CN1313465C (enExample)
AT (1) ATE307129T1 (enExample)
AU (1) AU780191B2 (enExample)
BG (1) BG65586B1 (enExample)
BR (1) BR0013427A (enExample)
CA (1) CA2381975A1 (enExample)
CY (1) CY1105253T1 (enExample)
CZ (1) CZ2002599A3 (enExample)
DE (1) DE60023318T2 (enExample)
DK (1) DK1210344T3 (enExample)
EE (1) EE200200079A (enExample)
ES (1) ES2250177T3 (enExample)
HU (1) HUP0202757A3 (enExample)
IL (2) IL148157A0 (enExample)
IS (1) IS6275A (enExample)
MX (1) MXPA02001764A (enExample)
NO (1) NO322460B1 (enExample)
NZ (1) NZ517221A (enExample)
PL (1) PL353825A1 (enExample)
RU (1) RU2296127C9 (enExample)
SK (1) SK2512002A3 (enExample)
UA (1) UA75871C2 (enExample)
WO (1) WO2001012627A1 (enExample)
ZA (1) ZA200201358B (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
CA2438991C (en) * 2001-02-21 2010-08-17 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US6916821B2 (en) 2001-04-02 2005-07-12 Brown University Methods of treating disorders with Group I mGluR antagonists
WO2002078745A2 (en) * 2001-04-02 2002-10-10 Brown University Research Foundation Use of mglur5 antagonists in the manufacture of a medicament in the treatment of autism, mental retardation, schizophrenia
ES2295441T3 (es) * 2001-12-18 2008-04-16 MERCK & CO., INC. Moduladores de pirazol heteroaril sustituido de receptor 5 metabotropico de glutamato.
EP1458708B1 (en) * 2001-12-18 2007-09-26 Merck & Co., Inc. Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
EP1458385A4 (en) * 2001-12-19 2005-12-21 Merck & Co Inc METABOTROPIC GLUTAMATE RECEPTOR 5-HETEROARYL-SUBSTITUTED IMIDAZOLE MODULATORS
ATE486600T1 (de) * 2002-03-12 2010-11-15 Merck Sharp & Dohme Di-aryl-substituierte tetrazol-modulatoren des metabotropen glutamat-rezeptors-5
US7964609B2 (en) 2002-06-20 2011-06-21 Astrazeneca Ab Use of mGluR5 antagonists for the treatment of gerd
SE0201943D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New use
AR040847A1 (es) 2002-08-09 2005-04-20 Astrazeneca Ab 1,2,4-oxadiazoles como moduladores de receptores de glutamato metabotropicos, para el tratamiento de desordenes neurologicos y psiquiatricos
WO2004014902A2 (en) * 2002-08-09 2004-02-19 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
TW200424183A (en) * 2002-08-09 2004-11-16 Nps Pharma Inc New compounds
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
AU2004227833B2 (en) * 2003-04-04 2009-10-01 Merck & Co., Inc. Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
CA2524867A1 (en) * 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
WO2005060961A2 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
BRPI0418149A (pt) 2003-12-24 2007-04-17 Prosidion Ltd derivados heterocìclicos como agonistas do receptor de gprc
AU2005214378A1 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
US20070185095A1 (en) * 2004-02-18 2007-08-09 Astrazeneca Ab Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
TW200538108A (en) 2004-02-19 2005-12-01 Astrazeneca Ab Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2006004142A1 (ja) * 2004-06-30 2006-01-12 Banyu Pharmaceutical Co., Ltd. ビアリール誘導体
KR100621192B1 (ko) * 2004-10-13 2006-09-19 한국화학연구원 무스카린 수용체 작용물질로서 작용하는1,2,3,4-테트라하이드로피리미디닐-1,2,4-옥사다이아졸유도체와 이의 제조방법
JP4557685B2 (ja) 2004-11-15 2010-10-06 独立行政法人理化学研究所 蛍光蛋白質
CA2593439C (en) 2005-01-14 2014-02-25 F. Hoffmann-La Roche Ag Thiazole-4-carboxamide derivatives as mglur5 antagonists
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
EP1896011A1 (en) * 2005-06-28 2008-03-12 AstraZeneca AB New use
AU2006272978B2 (en) 2005-07-26 2012-06-07 Bial - Portela & Ca, S.A. Nitrocatechol derivatives as COMT inhibitors
AR058807A1 (es) 2005-09-29 2008-02-27 Astrazeneca Ab 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5
JP5015166B2 (ja) 2005-11-08 2012-08-29 エフ．ホフマン−ラ ロシュ アーゲー ｍＧｌｕ５受容体アンタゴニストとしてのチアゾロ［４，５−ｃ］ピリジン誘導体
US7951824B2 (en) 2006-02-17 2011-05-31 Hoffman-La Roche Inc. 4-aryl-pyridine-2-carboxyamide derivatives
MX2008012738A (es) * 2006-04-03 2009-02-06 Astellas Pharma Inc Heterocompuesto.
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
US20100234349A1 (en) * 2006-09-04 2010-09-16 Olsen Gunnar M Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
CL2007002593A1 (es) 2006-09-07 2008-06-13 Actelion Pharmaceuticals Ltd Compuestos derivados de 4-heteroaril-piridina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como rechazo de organos transplantados, sindromes autoinmunes y cancer.
SI2069335T1 (sl) 2006-09-08 2013-04-30 Actelion Pharmaceuticals Ltd. Derivati piridin-3-ila kot imunomodulacijska sredstva
EP2069318B1 (en) 2006-09-21 2012-09-12 Actelion Pharmaceuticals Ltd. Phenyl derivatives and their use as immunomodulators
CN101631548B (zh) 2007-01-31 2014-08-27 比艾尔-坡特拉有限公司 Comt抑制剂的单次药物剂量单元和药物组合物
JP2010521450A (ja) 2007-03-16 2010-06-24 アクテリオン ファーマシューティカルズ リミテッド Ｓ１ｐ１／ｅｄｇ１受容体アゴニストとしてのアミノ−ピリジン誘導体
PL2195311T3 (pl) 2007-08-17 2011-08-31 Actelion Pharmaceuticals Ltd Pochodne pirydynowe jako modulatory receptora S1P1/EDG1
JP2011502148A (ja) 2007-10-31 2011-01-20 メルク・シャープ・エンド・ドーム・コーポレイション 疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト
CN101970430B (zh) 2007-11-01 2013-05-08 埃科特莱茵药品有限公司 嘧啶衍生物
RS52270B (sr) * 2007-12-20 2012-10-31 Bayer Pharma Aktiengesellschaft 4-(4-cijano-2-tioaril)-dihidropirimidinon i njegova primena
CN101990433B (zh) 2008-02-07 2014-11-05 马萨诸塞眼科耳科诊所 提高Atoh1表达的化合物
BRPI0910288A2 (pt) 2008-03-07 2019-09-24 Actelion Pharmaceuticals Ltd composto de derivados de aminometil benzeno, composição farmacêutica que compreende esse composto e uso do mesmo.
AU2009226221A1 (en) 2008-03-17 2009-09-24 Bial - Portela & Ca., S.A. Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,3] oxadiazol-5-yl] -3-nit robenzene-1, 2-diol
US8598209B2 (en) 2008-10-31 2013-12-03 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
DE102009041242A1 (de) 2009-09-11 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057344A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057343A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041241A1 (de) 2009-09-11 2011-08-04 Bayer Schering Pharma Aktiengesellschaft, 13353 Substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057364A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Substituierte Aryl-Verbindungen und ihre Verwendung
AU2010229142A1 (en) 2009-03-23 2011-10-13 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
US8946231B2 (en) 2009-03-23 2015-02-03 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
ES2660892T3 (es) 2009-03-23 2018-03-26 Merck Sharp & Dohme Corp. Antagonistas del receptor P2X3 para el tratamiento del dolor
KR102023255B1 (ko) 2009-04-01 2019-09-19 바이알 - 포르텔라 앤드 씨에이 에스에이 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법
CA2758587A1 (en) * 2009-04-13 2010-10-21 Irm Llc Compositions and methods for modulating retinol binding to retinol binding protein 4 (rbp4)
KR101409131B1 (ko) 2009-07-16 2014-06-17 액테리온 파마슈티칼 리미티드 피리딘-4-일 유도체
US20130058915A1 (en) 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
SG191742A1 (en) 2011-01-19 2013-08-30 Actelion Pharmaceuticals Ltd 2-methoxy-pyridin-4-yl derivatives
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
BR112014014341A2 (pt) 2011-12-13 2017-08-22 Bial Portela & Ca Sa Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica
JP5946288B2 (ja) * 2012-02-24 2016-07-06 公立大学法人名古屋市立大学 新規ヒドロキサム酸誘導体及びその用途
UY35327A (es) 2013-02-15 2014-09-30 Monsanto Technology Llc ?4,5-dihidro-1,2,4-oxadiazoles disustituidos en 3,5 y composiciones y métodos para controlar plagas de nematodos?.
EP2853532B1 (en) * 2013-09-28 2020-12-09 Instytut Farmakologii Polskiej Akademii Nauk 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III
WO2016083863A1 (en) 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease
MY192358A (en) 2015-05-20 2022-08-17 Idorsia Pharmaceuticals Ltd Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
AU2016281346B2 (en) 2015-06-23 2020-01-02 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, or pharmaceutically acceptable salt thereof
MX2018011765A (es) * 2016-03-30 2019-05-20 Sinntaxis AB Moduladores alostéricos negativos del receptor 5 metabotrópico de glutamato (mglur5) para su uso en el tratamiento de daños cerebrales maduros.
ES2965174T3 (es) * 2018-04-12 2024-04-11 Bayer Ag Derivados de N-(ciclopropilmetil)-5-(metilsulfonil)-n-{1-[1-(pirimidin-2-il)-1H-1,2,4-triazol-5-il]etil}heterociclilamida y compuestos similares como plaguicidas
KR102276327B1 (ko) * 2019-06-25 2021-07-12 연세대학교 산학협력단 신규 옥사다이아졸 화합물 및 이를 포함하는 당뇨 예방 또는 치료용 조성물
WO2021046183A1 (en) * 2019-09-05 2021-03-11 Trevena, Inc. Methods of treating epilepsy using the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1149011B (de) * 1960-04-05 1963-05-22 Hoechst Ag Verfahren zur Herstellung von 3, 5-disubstituierten 1, 2, 4-Oxdiazolen
US3647809A (en) * 1968-04-26 1972-03-07 Chinoin Gyogyszer Es Vegyeszet Certain pyridyl-1 2 4-oxadiazole derivatives
US4003909A (en) * 1974-07-22 1977-01-18 E. R. Squibb & Sons, Inc. [(1,2,4-Oxadiazol-3-yl)phenyl]carbamic or thiocarbamic acid esters
US4022901A (en) * 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
AU675484B2 (en) * 1993-03-24 1997-02-06 Neurosearch A/S Benzimidazole compounds, their use and preparation
US5554630A (en) * 1993-03-24 1996-09-10 Neurosearch A/S Benzimidazole compounds
WO1994022846A1 (en) * 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
RU2135493C1 (ru) * 1995-04-21 1999-08-27 Нюросерч А/С Производное бензимидазола, фармацевтический состав и способ модуляции гамка-рецепторного комплекса
WO1997003967A1 (en) * 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
DE19643037A1 (de) * 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
WO1999026927A2 (en) * 1997-11-21 1999-06-03 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists for treating central nervous system diseases

Also Published As

Publication number Publication date
RU2296127C2 (ru) 2007-03-27
NZ517221A (en) 2004-01-30
AU6782400A (en) 2001-03-13
CN1379775A (zh) 2002-11-13
BG106493A (en) 2003-01-31
ES2250177T3 (es) 2006-04-16
SK2512002A3 (en) 2002-07-02
NO20020823D0 (no) 2002-02-19
EP1210344A1 (en) 2002-06-05
EE200200079A (et) 2003-06-16
MXPA02001764A (es) 2004-03-19
HK1047929A1 (en) 2003-03-14
BR0013427A (pt) 2002-07-30
RU2296127C9 (ru) 2007-08-27
IS6275A (is) 2002-02-18
DE60023318T2 (de) 2006-07-20
UA75871C2 (en) 2006-06-15
CA2381975A1 (en) 2001-02-22
ZA200201358B (en) 2003-07-30
HUP0202757A3 (en) 2006-03-28
AU780191B2 (en) 2005-03-03
EP1210344B1 (en) 2005-10-19
JP2003507378A (ja) 2003-02-25
IL148157A (en) 2007-07-04
IL148157A0 (en) 2002-09-12
CY1105253T1 (el) 2010-03-03
HUP0202757A2 (hu) 2002-12-28
DK1210344T3 (da) 2006-03-06
BG65586B1 (bg) 2009-01-30
NO322460B1 (no) 2006-10-09
KR20020038731A (ko) 2002-05-23
KR100875222B1 (ko) 2008-12-19
NO20020823L (no) 2002-04-17
CZ2002599A3 (cs) 2002-06-12
WO2001012627A1 (en) 2001-02-22
ATE307129T1 (de) 2005-11-15
CN1313465C (zh) 2007-05-02
JP2006143746A (ja) 2006-06-08
DE60023318D1 (de) 2006-03-02
PL353825A1 (en) 2003-12-01

Similar Documents

Publication Publication Date Title
KR100875222B1 (ko) 헤테로폴리사이클릭 화합물 및 간접 글루타메이트 수용체길항제로서의 그들의 용도
JP4519404B2 (ja) ヘテロ多環式化合物およびその代謝型グルタミン酸受容体アンタゴニストとしての使用
US6660753B2 (en) Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
AU2002306517A1 (en) Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US10793529B2 (en) Substituted pyridazines and 1,2,4-triazines as prostacyclin receptor modulators
US20060189661A1 (en) Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
EP1582519A2 (en) Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
HK1047929B (en) Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
HK1093734A (en) Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050128

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20050128

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20050304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050726

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20051026

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20051104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20060307

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20060331

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090407

Year of fee payment: 3

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090407

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090407

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100407

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110407

Year of fee payment: 5

LAPS Cancellation because of no payment of annual fees